tetano
Editor, Senior Moderator
Antiviral Res. 2016 Jan 20. pii: S0166-3542(16)30007-9. doi: 10.1016/j.antiviral.2016.01.005. [Epub ahead of print]
[h=1]Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.[/h] Lin C[SUP]1[/SUP], Sun C[SUP]2[/SUP], Liu X[SUP]2[/SUP], Zhou Y[SUP]1[/SUP], Hussain M[SUP]3[/SUP], Wan J[SUP]1[/SUP], Li M[SUP]1[/SUP], Li X[SUP]2[/SUP], Jin R[SUP]4[/SUP], Tu Z[SUP]5[/SUP], Zhang J[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Among many subtypes of influenza A viruses, influenza A(H1N1) and A(H3N2) subtypes are currently circulating among humans (WHO report 2014-15). Therapeutically, the emergence of viral resistance to currently available drugs (adamantanes and neuraminidase inhibitors) has heightened alarms for developing novel drugs that could address diverse targets in the viral replication cycle in order to improve treatment outcomes. To this regard, the design and synthesis of nucleoside analog inhibitors as potential anti-influenza A agents is a very active field of research nowadays. In this study, we designed and synthesized a series of hitherto unknown 6-methyl-7-substituted-7-deaza purine nucleoside analogs, and evaluated for their biological activities against influenza A virus strains, H1N1 and H3N2. From the viral inhibition assay, we identified some effective compounds, among which, compounds 5x (IC[SUB]50[/SUB] = 5.88 μM and 6.95 μM for H1N1 and H3N2, respectively) and 5z (IC[SUB]50[/SUB] = 3.95 μM and 3.61 μM for H1N1 and H3N2, respectively) demonstrated potent anti-influenza A activity. On the basis of selectivity index, we conceive that compound 5x may serve as a chemical probe of interest for further lead optimization studies with a general aim of developing novel and effective anti-influenza A virus agents.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] H1N1; H3N2; Influenza A; Nucleoside analogs
PMID: 26802557 [PubMed - as supplied by publisher]
[h=1]Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.[/h] Lin C[SUP]1[/SUP], Sun C[SUP]2[/SUP], Liu X[SUP]2[/SUP], Zhou Y[SUP]1[/SUP], Hussain M[SUP]3[/SUP], Wan J[SUP]1[/SUP], Li M[SUP]1[/SUP], Li X[SUP]2[/SUP], Jin R[SUP]4[/SUP], Tu Z[SUP]5[/SUP], Zhang J[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Among many subtypes of influenza A viruses, influenza A(H1N1) and A(H3N2) subtypes are currently circulating among humans (WHO report 2014-15). Therapeutically, the emergence of viral resistance to currently available drugs (adamantanes and neuraminidase inhibitors) has heightened alarms for developing novel drugs that could address diverse targets in the viral replication cycle in order to improve treatment outcomes. To this regard, the design and synthesis of nucleoside analog inhibitors as potential anti-influenza A agents is a very active field of research nowadays. In this study, we designed and synthesized a series of hitherto unknown 6-methyl-7-substituted-7-deaza purine nucleoside analogs, and evaluated for their biological activities against influenza A virus strains, H1N1 and H3N2. From the viral inhibition assay, we identified some effective compounds, among which, compounds 5x (IC[SUB]50[/SUB] = 5.88 μM and 6.95 μM for H1N1 and H3N2, respectively) and 5z (IC[SUB]50[/SUB] = 3.95 μM and 3.61 μM for H1N1 and H3N2, respectively) demonstrated potent anti-influenza A activity. On the basis of selectivity index, we conceive that compound 5x may serve as a chemical probe of interest for further lead optimization studies with a general aim of developing novel and effective anti-influenza A virus agents.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] H1N1; H3N2; Influenza A; Nucleoside analogs
PMID: 26802557 [PubMed - as supplied by publisher]